China Isotope & Radiation (SEHK:1763) - Share price, News & Analysis

1763 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	4/6
Financial Health	6/6
Dividends	2/6

1763 Stock Overview

Rewards

Trading at 33.4% below our estimate of its fair value

Earnings are forecast to grow 14.46% per year

Earnings grew by 57.2% over the past year

Risk Analysis

No risks detected for 1763 from our risk checks.

China Isotope & Radiation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for China Isotope & Radiation
Historical stock prices
Current Share Price	HK$17.70
52 Week High	HK$32.10
52 Week Low	HK$17.04
Beta	0.82
1 Month Change	-8.67%
3 Month Change	-19.55%
1 Year Change	-44.34%
3 Year Change	-3.91%
5 Year Change	n/a
Change since IPO	-11.94%

Recent News & Updates

Jun 10

Is There Now An Opportunity In China Isotope & Radiation Corporation (HKG:1763)?

While China Isotope & Radiation Corporation ( HKG:1763 ) might not be the most widely known stock at the moment, it saw...

Shareholder Returns

	1763	HK Medical Equipment	HK Market
7D	-2.2%	15.3%	2.1%
1Y	-44.3%	-60.3%	-23.3%

Return vs Industry: 1763 exceeded the Hong Kong Medical Equipment industry which returned -60.3% over the past year.

Return vs Market: 1763 underperformed the Hong Kong Market which returned -23.3% over the past year.

Price Volatility

Is 1763's price volatile compared to industry and market?
1763 volatility
1763 Average Weekly Movement	5.4%
Medical Equipment Industry Average Movement	9.1%
Market Average Movement	7.0%
10% most volatile stocks in HK Market	13.8%
10% least volatile stocks in HK Market	3.3%

Stable Share Price: 1763 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 1763's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1983	3,120	n/a	https://www.circ.com.cn

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits.

China Isotope & Radiation Fundamentals Summary

How do China Isotope & Radiation's earnings and revenue compare to its market cap?
1763 fundamental statistics
Market Cap	CN¥4.83b
Earnings (TTM)	CN¥335.75m
Revenue (TTM)	CN¥5.14b

14.4x

P/E Ratio

0.9x

P/S Ratio

Is 1763 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
1763 income statement (TTM)
Revenue	CN¥5.14b
Cost of Revenue	CN¥1.90b
Gross Profit	CN¥3.24b
Other Expenses	CN¥2.91b
Earnings	CN¥335.75m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	1.05
Gross Margin	63.03%
Net Profit Margin	6.53%
Debt/Equity Ratio	12.6%

How did 1763 perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

36%

Payout Ratio

We’ve recently updated our valuation analysis.

Valuation

Is 1763 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1763?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 1763. This is calculated by dividing 1763's market cap by their current preferred multiple.
What is 1763's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	CN¥4.83b

1763 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	5.3x
PEG Ratio	1x

Price to Earnings Ratio vs Peers

How does 1763's PE Ratio compare to its peers?

1763 PE Ratio vs Peers

The above table shows the PE ratio for 1763 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PE	Estimated Growth	Market Cap
Peer Average	142.4x

Forward PE

Price-To-Earnings vs Peers: 1763 is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (142.4x).

Price to Earnings Ratio vs Industry

How does 1763's PE Ratio compare vs other companies in the Medical Equipment Industry?

Price-To-Earnings vs Industry: 1763 is good value based on its Price-To-Earnings Ratio (14.4x) compared to the Hong Kong Medical Equipment industry average (17.1x)

Price to Earnings Ratio vs Fair Ratio

What is 1763's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1763 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	14.4x
Fair PE Ratio	12.6x

Price-To-Earnings vs Fair Ratio: 1763 is expensive based on its Price-To-Earnings Ratio (14.4x) compared to the estimated Fair Price-To-Earnings Ratio (12.6x).

Share Price vs Fair Value

What is the Fair Price of 1763 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1763 (HK$17.7) is trading below our estimate of fair value (HK$26.59)

Significantly Below Fair Value: 1763 is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: 1763 is good value based on its PEG Ratio (1x)

Discover undervalued companies

Future Growth

How is China Isotope & Radiation forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

14.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1763's forecast earnings growth (14.5% per year) is above the savings rate (1.5%).

Earnings vs Market: 1763's earnings (14.5% per year) are forecast to grow slower than the Hong Kong market (17% per year).

High Growth Earnings: 1763's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1763's revenue (14.3% per year) is forecast to grow faster than the Hong Kong market (10.3% per year).

High Growth Revenue: 1763's revenue (14.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1763's Return on Equity is forecast to be low in 3 years time (10.3%).

Discover growth companies

Past Performance

How has China Isotope & Radiation performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-1.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 1763 has high quality earnings.

Growing Profit Margin: 1763's current net profit margins (6.5%) are higher than last year (5%).

Past Earnings Growth Analysis

Earnings Trend: 1763's earnings have declined by 1.9% per year over the past 5 years.

Accelerating Growth: 1763's earnings growth over the past year (57.2%) exceeds its 5-year average (-1.9% per year).

Earnings vs Industry: 1763 earnings growth over the past year (57.2%) exceeded the Medical Equipment industry 35.4%.

Return on Equity

High ROE: 1763's Return on Equity (11.2%) is considered low.

Discover strong past performing companies

Financial Health

How is China Isotope & Radiation's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: 1763's short term assets (CN¥6.7B) exceed its short term liabilities (CN¥4.0B).

Long Term Liabilities: 1763's short term assets (CN¥6.7B) exceed its long term liabilities (CN¥470.9M).

Debt to Equity History and Analysis

Debt Level: 1763 has more cash than its total debt.

Reducing Debt: 1763's debt to equity ratio has reduced from 32.5% to 12.6% over the past 5 years.

Debt Coverage: 1763's debt is well covered by operating cash flow (104.1%).

Interest Coverage: 1763's interest payments on its debt are well covered by EBIT (243.7x coverage).

Balance Sheet

Discover healthy companies

Dividend

What is China Isotope & Radiation current dividend yield, its reliability and sustainability?

Dividend Score

1/6

Dividend Score 1/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

2.47%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 1763's dividend (2.47%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.74%).

High Dividend: 1763's dividend (2.47%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.89%).

Stability and Growth of Payments

Stable Dividend: 1763 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 1763's dividend payments have increased, but the company has only paid a dividend for 4 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (36%), 1763's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (32.5%), 1763's dividend payments are well covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average board tenure

CEO

China Isotope & Radiation has no CEO, or we have no data on them.

Board Members

Experienced Board: 1763's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/26 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31